Biofrontera Inc. Profile
Industry
Drug Manufacturers - Specialty & GenericSector
HealthcareNumber of Employees
83Biofrontera's Business Model
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
About Biofrontera
Website: https://www.biofrontera.us.com
CEO (Chief Executive Officer): Dr. Hermann Luebbert Ph.D.
IPO date: 2021-10-29
Contact
Country: US
Address: 120 Presidential Way
City: Woburn
State: MA
Phone: 781 245 1325
Zip Code: 01801
Other
CIK: 0001858685
ISIN: US09077D2099
CUSIP: 09077D100
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
